CTM-N2D / CytoMed Therap - LARVOL DELTA

SunAct & CytoMed join hands for Ph 2 clinical trials of innovative cancer therapy in India (Biospectrumasia) - "India's SunAct Cancer Institute has announced the start of Phase 2 clinical trials on a groundbreaking treatment called gd (Gamma Delta) T-cell therapy. This trial, conducted in collaboration with CytoMed, Singapore, aims to bring hope to patients with difficult-to-treat cancers such as brain cancer, breast cancer, lung cancer, cervical cancer, colon cancer, renal cancer, liver cancer , lymph node cancer and several others....The trial will begin in early 2025, and patients will soon be able to enroll."

Commercial • New P2 trial • Brain Cancer • Breast Cancer • Cervical Cancer • Colon Cancer • Liver Cancer • Lung Cancer • Oncology • Renal Cell Carcinoma

Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: CytoMed Therapeutics Pte Ltd | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2023 ➔ Dec 2026 | Trial primary completion date: Mar 2023 ➔ Nov 2025

Enrollment open • Metastases • Trial completion date • Trial primary completion date • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor • NKG2D

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies (GlobeNewswire) - "Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited...is pleased to announce that the first patient has been dosed in its first-in-human Phase I dose-escalation clinical trial (NCT05302037) ('ANGELICA Trial'). This trial has been registered with and has received clinical trial authorisation from the Health Sciences Authority in Singapore."

Trial status • Oncology • Solid Tumor

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant (GlobeNewswire) - "CytoMed Therapeutics Limited...has obtained full approval for its first-in-human Phase I clinical trial ('ANGELICA Trial') using its patented allogeneic chimeric antigen receptor T cell ('CAR-T cell') against several blood and solid tumors in collaboration with the National University Hospital ('NUH') of Singapore. The ANGELICA Trial is co-supported by the Singapore Ministry of Health through the National Medical Research Council ('NMRC') Office, and MOH Holdings Pte Ltd under the NMRC Clinical Trial Grant Industry Collaborative Trials (CTG-ICT) scheme (MOH-001646)."

Financing • Oncology • Solid Tumor

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire) - "Clinical Updates...The ANGELICA Trial comprises two parts. Part 1 (donor protocol) is ongoing with the recruitment of healthy blood donors at NUH. With the continued collaboration between CytoMed and NUH, the second part of the trial (recipient protocol) may now proceed with the recruitment of patients who have advanced cancers that are resistant to standard therapy regimens....As of September 2024, the Company is translating two proprietary, exclusively licensed technologies, namely donor blood cell-based CAR-γδ T cell technology and induced pluripotent stem cell-based γδ NKT cell technology. The former has been granted patents in the US, China and Malaysia, the latter in China, Japan and Malaysia."

Patent • Trial status • Hematological Malignancies • Oncology • Solid Tumor

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology (GlobeNewswire) - "CytoMed Therapeutics Limited...announced...that the Intellectual Property Corporation of Malaysia has granted a patent for its chimeric antigen receptor gamma delta T cell ('CAR-γδ T cell') technology, which targets solid and hematological tumors...The patent titled 'Gamma Delta T Cells and a Method of Augmenting the Tumoricidal Activity of the Same' (Patent number: MY-200528-A) covers technologies for the clinical-scale expansion of γδ T cells from a small amount of donor peripheral blood cells, as well as the modification of the expanded γδ T cells to incorporate a chimeric antigen receptor...As a separate update, the Company has on January 12, 2024 submitted a drug master file to the US Food and Drug Administration in preparation for an investigational new drug filing to treat hematological and solid cancers using our allogeneic γδ T cells."

IND • Patent • Hematological Malignancies

A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US (PRNewswire) - "CytoMed Therapeutics Limited...announce that the CAR-gamma delta T cell (CAR-γδ T cell) technology, which it has exclusively licensed from A*STAR, has been granted a patent by the US Patent and Trademark Office (USPTO). The patent...covers technologies for the clinical-scale expansion of γδ T cells from a small amount of donor peripheral blood cells as well as the modification of the expanded γδ T cells to incorporate a chimeric antigen receptor (CAR) that enables the modified cells to recognize a wide range of cancers, including both solid and hematologic cancers. CytoMed holds an exclusive, worldwide license, for use on immunotherapy, including stem cell therapy, until the expiration of the patent covering technology."

Patent • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Head and Neck Cancer • Hematological Malignancies • Liver Cancer • Lung Cancer • Lymphoma • Multiple Myeloma • Nasopharyngeal Carcinoma • Oncology • Ovarian Cancer • Prostate Cancer • Sarcoma • Solid Tumor • Thoracic Cancer • Triple Negative Breast Cancer • Urothelial Cancer

The IPO Buzz: China & Malaysia in April’s Micro-Cap Mix (IPOScoop.com) - "CytoMed expects to recruit its first patient in the second half of 2023 for the ANGELICA clinical trial of its CTM-N2D drug candidate in Singapore. The company expects to begin pre-clinical studies after 2024 for its other leading drug candidate program – its iPSC-gdNKT platform."

Preclinical • Trial status • Hematological Malignancies • Oncology • Solid Tumor

CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering (PRNewswire) - "CytoMed Therapeutics Limited...announced the pricing of its initial public offering of its 2,412,369 ordinary shares at a price of US$4.00 per share, for gross proceeds of US$9,649,476.00 before deducting underwriting discounts, commissions and offering expenses....The net proceeds from the initial public offering will be used to advance the clinical development of the Company's CTM-N2D product candidate; to continue technology development of the Company's iPSC-gdNKT product candidate; to advance clinical development of the Company's CTM-GDT product candidate; and the remainder to fund R&D activities and manufacturing expansion, and for working capital and general corporate purposes."

Financing • Oncology • Solid Tumor

ANGELICA: Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: CytoMed Therapeutics Pte Ltd

New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor • NKG2D